Chronic Pain Haunts Millions of Cancer Survivors, Landmark Review Finds

For millions of people who have finished cancer treatment, the disease leaves behind a quieter companion that can outlast remission by decades: chronic pain. A new systematic review published in the Journal of Cancer Survivorship has pulled together the scattered evidence on how common this pain is, what mechanisms drive it, and how deeply it erodes mental health. The analysis, conducted by Zhuldyz Myrzabay of Nazarbayev University and Dmitriy Viderman of the National Research Oncology Center in Kazakhstan, synthesizes 32 studies published between 2011 and 2026 and paints a picture of a problem that is both widespread and stubbornly under-addressed in routine survivorship care.

The headline finding is the sheer variability of the numbers. Among established long-term survivor cohorts, chronic pain prevalence ranged from 8.6 percent to 67.1 percent, a nearly eightfold spread that reflects differences in cancer type, treatment regimens, time since treatment, and how pain itself was measured. Head and neck cancer survivors, breast cancer survivors treated with surgery and radiotherapy, and patients who received neurotoxic chemotherapy all feature prominently in the evidence base. The authors caution that this heterogeneity is not simply statistical noise; it signals that chronic pain after cancer is not one condition but a family of conditions with different biological origins and different trajectories.

To understand why pain persists long after tumors are removed, the review turned to modern mechanistic classifications of chronic pain. Neuropathic pain, caused by direct damage or disease affecting the somatosensory nervous system, emerged as the most frequently reported mechanism across the included studies. This is biologically plausible: surgical dissection can sever peripheral nerves, radiation can injure nerve plexuses, and chemotherapeutic agents such as taxanes and platinum compounds are well known for causing peripheral neuropathy. In colorectal cancer survivors followed for up to eleven years in population-based registry studies, chemotherapy-induced neuropathy was associated with measurably worse quality of life, and in head and neck populations, radiation-induced nervous system complications were linked to persistent pain syndromes.

But the review also highlights a more controversial and scientifically intriguing category: nociplastic pain. Introduced into the International Classification of Diseases through the International Association for the Study of Pain’s ICD-11 framework, nociplastic pain arises from altered nociceptive processing despite no clear evidence of actual or threatened tissue damage or of a lesion in the somatosensory system. Some survivor populations in the review showed symptom profiles consistent with this mechanism, including patterns suggestive of central sensitization, in which the central nervous system becomes hyperexcitable and amplifies pain signals. Breast cancer survivor cohorts assessed with instruments such as the Central Sensitization Inventory showed that a subset of patients experience pain that cannot be explained by nerve damage or tissue injury alone.

Here the authors insert an important scientific caveat. Most mechanistic classifications in the reviewed studies were based on screening instruments and symptom questionnaires rather than diagnostic confirmation through quantitative sensory testing or other objective measures. Central sensitization, in particular, remains a construct that is easy to describe but difficult to verify. The certainty of evidence across the three outcome domains of prevalence, mechanism, and psychological impact was evaluated using the GRADE framework, and the authors are candid that the mechanistic evidence remains suggestive rather than definitive. This is a call to the research community: the field needs rigorous phenotyping studies that combine psychophysical testing, imaging, and longitudinal follow-up to move beyond symptom-based surrogates.

The psychological toll of persistent pain emerges as the review’s most consistent finding. Across the included studies, cancer survivors with chronic pain reported higher levels of anxiety, more severe depressive symptoms, greater emotional distress, and poorer quality of life than pain-free survivors. This comorbidity is not incidental. Decades of research on depression and pain comorbidity show that the two conditions share neurotransmitter pathways and amplify each other in a vicious cycle: pain disrupts sleep, sleep loss lowers pain thresholds and worsens mood, and depression reduces the motivation and energy needed for rehabilitation and self-management. Studies in the review found that post-traumatic stress symptoms arising from multiple cancer-related stressors predicted chronic pain, and that pain catastrophizing, the tendency to ruminate and magnify pain, was elevated in survivors with refractory postsurgical pain.

The functional consequences extend beyond mood. Research on working-age survivors has linked chronic pain to reduced health-related quality of life and to difficulties maintaining employment, a burden with obvious economic and social dimensions. For head and neck cancer survivors, pain often coexists with difficulties in swallowing, speaking, and shoulder function, compounding the impact on daily life. In breast cancer populations, persistent pain after treatment has been described as an underreported burden, with many patients never raising the issue during follow-up visits and clinicians rarely asking. The review’s implications section is direct: survivors should report ongoing pain and emotional symptoms, and survivorship care should include routine assessment of both.

Methodologically, the review is a model of transparency. The authors searched five major databases, PubMed, Scopus, Web of Science, Embase, and PsycINFO, registered their protocol prospectively in PROSPERO, appraised methodological quality with the Joanna Briggs Institute critical appraisal tools, and followed the PRISMA 2020 reporting guidelines. The included studies were predominantly cross-sectional and cohort designs covering a wide range of malignancies, from melanoma and testicular cancer to colorectal, breast, lung, and prostate cancers. No new primary data were generated; the analysis is entirely a synthesis of previously published work, with supporting data available in the article’s supplementary materials.

What should clinicians and patients take away from this body of evidence? First, chronic pain after cancer is common enough that it should be screened for systematically, not discovered only when a patient volunteers the information. The American Society of Clinical Oncology has long had a clinical practice guideline for managing chronic pain in adult cancer survivors, yet the review suggests that long-term care strategies remain lacking in practice. Second, because the mechanisms differ, treatment should differ: neuropathic pain may respond to different classes of medication than nociplastic pain, which often benefits from exercise, cognitive behavioral approaches, and centrally acting strategies. Multidimensional pain assessment, covering sensory qualities, psychological state, sleep, and function, is the practical corollary of the review’s mechanistic message.

Finally, the review identifies where science must go next. Stronger mechanistic research is needed to distinguish reliably between neuropathic, nociceptive, and nociplastic contributions in individual patients, and longitudinal studies should track how pain phenotypes evolve from the end of treatment into long-term survivorship. Emerging tools, including wearable devices capable of continuously monitoring pain-related parameters, may eventually help predict which patients are at highest risk before pain becomes entrenched. For now, the message for the growing global population of cancer survivors is clear: pain that persists after treatment is a medical condition in its own right, it is strongly linked to mental health, and it deserves the same systematic attention that surveillance for cancer recurrence already receives.

Subject of Research: Prevalence, mechanisms, and psychological outcomes of chronic pain in cancer survivors

Article Title: Prevalence, mechanisms, and psychological outcomes of chronic pain in cancer survivors: a systematic review with narrative synthesis

Article References: Myrzabay, Z., & Viderman, D. (2026). Prevalence, mechanisms, and psychological outcomes of chronic pain in cancer survivors: a systematic review with narrative synthesis. Journal of Cancer Survivorship. https://doi.org/10.1007/s11764-026-02138-7

Image Credits: AI Generated

DOI: 10.1007/s11764-026-02138-7

Keywords: cancer survivors, chronic pain, neuropathic pain, nociplastic pain, central sensitization, psychological outcomes, quality of life, systematic review, chemotherapy-induced neuropathy, survivorship care, depression, anxiety